A Phase 3b, Multi-Center, Randomized-withdrawal, Placebo-Controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45-120mg/day, Split-dose) in Subjects with Chronic Kidney Disease Stage 4 due to Autosomal Dominant Polycystic Kidney Disease.
Department of Orthopaedics researchers have published a
study that finds there is no statistically significant difference
in clinical outcomes after arthroscopic partial meniscectomy among
normal weight and obese patients.
Thirteen faculty members with a variety of research and clinical
experience — representing six medical school departments
— have joined the Jacobs School of Medicine and Biomedical
Sciences over the past several months.